Katie Insogna > DLA Piper LLP (US) > Boston, United States > Lawyer Profile

DLA Piper LLP (US)
BOSTON MA 02110-1447
United States

Work Department

Litigation, Arbitration and Investigations


Partner; Co-Chair, Pharmaceutical and Medical Device Product Liability Sub-practice Group


Katie Insogna’s practice focuses on the defense of pharmaceutical, life science and medical device companies in a variety of cases, including multidistrict product liability litigation and complex commercial litigation.

Katie has extensive expertise with fact and expert witness development, discovery and dispositive motion practice, and trial preparation. Katie has taken and defended numerous party and third-party witness depositions in product liability and commercial litigation cases. She also has argued motions in state and federal courts.


J.D., University of Southern California Gould School of Law; B.A., Georgetown University

Lawyer Rankings

United States > Dispute resolution > Product liability, mass tort and class action - defense: pharmaceuticals and medical devices

(Next Generation Partners)

Katie InsognaDLA Piper LLP (US)

The ‘extremely responsive and thoughtful’ team at DLA Piper LLP (US) provides an ‘excellent client service and medical device knowledge’ to a wide range of pharmaceuticals companies, including Sanofi and Bayer, across a range of major product liability mandates. While the firm has a growing profile in trying cases, it is particularly adept at achieving an early conclusion of cases, through its effective use of dispositive pre-emption motions and Daubert challenges. Loren Brown in New York regularly acts as national co-ordinating counsel and lead trial counsel in mass torts and MDLs throughout the country, as well as in the context of global litigation – including her work for Bayer in mass tort litigation involving Essure. Based out of Atlanta, product liability chair Christopher Campbell is noted for his high-level strategic advice to manufacturers across a range of products, including many within the pharmaceutical space, where he is appreciated for his ‘guidance on the big picture’, as well his aptitude at handling cross-border mandates. Boston-based global co-chair of the firm’s life sciences sector, Matthew Holian is ‘super smart and very strategic‘ throughout the product life cycle, from risk assessment, pre-litigation discovery, bellwether trials and, ultimately, resolution. ‘Highly-skilled‘ Boston-based Katie Insogna excels at handling high-stakes litigation and counselling. Based out New York, Lucas Przymusinski provides ‘thoughtful guidance‘ to pharma companies across an array of regulatory and litigation matters, including product liability disputes, where his medical and science background provides additional benefit.

United States > Healthcare > Life sciences

(Next Generation Partners)

Katie InsognaDLA Piper LLP (US)

Clients praise DLA Piper LLP (US)‘s litigation offering, nothing that its ‘expert testimony is second to none.’ Product liability cases make up the majority of the team’s high profile work, including advising Sanofi, Bayer, and Novo Nordisk in state and federal court. It also advises pharmaceutical companies on consumer class actions. Commercially, the team acts on a transaction’s full life cycle, encompassing due diligence, company formation, and regulatory issues. Financing is another area of expertise, both via private placements and capital markets offerings. Matthew Holian and Andrew Gilbert co-chair the team from Boston and New Jersey respectively. New York-based Loren Brown heads the litigation practice, with extensive experience on mass torts cases. Baltimore-based Howard Schwartz acts on financings, and Boston-based Katie Insogna acts on product liability matters.